José Calle Gordo

Mr Jose Calle Gordo joined Biosensors in 2014 as the Chief Executive Officer and was then appointed as an Executive Director. In October 2016, he has been appointed as Vice Chairman of the Board of Directors of the new company, Cardio Holdings II Limited, after the privatization of Biosensors in April 2016.

He had a successful career with over 25 years of broad business and management experience in the medical devices industry, having served in various vice president and managerial roles at Abbott, Guidant and Eli Lilly. He led the global team that developed and commercialized Xience, a family of drug eluting stents (DES) and market leader for the treatment of coronary artery disease while serving as Vice President and General Manager of Drug Eluting Stents, Vascular Intervention at Guidant based in Santa Clara, California (US).

As Vice President of Abbott Vascular based in Brussels, he later managed the international operations of Abbott Vascular outside of the US and more recently he led globally the commercial introduction of bioresorbable vascular scaffolds (ABSORB BVS) and MitraClip, the world's first percutaneous mitral valve repair therapy.
During his earlier years with Guidant and Eli Lilly, he contributed in different managerial roles to the commercial and therapy development of the implanted defibrillator and cardiac resynchronization therapy.
Mr. Calle Gordo received his Biomedical/Medical Engineering (Electrical Engineering) degree from Universidad Politecnica de Madrid, Spain.